Skip to main content
EMVISION MEDICAL DEVICES LTD logo

EMVISION MEDICAL DEVICES LTD — Investor Relations & Filings

Ticker · EMV ISIN · AU0000028375 ASX Manufacturing
Open in API
Filings indexed 304 across all filing types
Latest filing 2023-05-04 Capital/Financing Update
Country AU Australia
Listing ASX EMV

About EMVISION MEDICAL DEVICES LTD

https://emvision.com.au/

EMVision Medical Devices Ltd is a medical technology company focused on the development and commercialization of portable medical imaging devices. The company specializes in electromagnetic microwave imaging technology designed for the rapid diagnosis and monitoring of stroke and traumatic brain injury. Its primary product is a portable brain scanner intended for use at the point of care, including intensive care units, emergency departments, and ambulances. By utilizing non-ionizing radiation, the technology provides a safe, cost-effective, and mobile alternative to traditional neuroimaging modalities like CT and MRI. The device aims to facilitate earlier clinical intervention by enabling bedside assessment, potentially improving patient outcomes through faster detection of ischemic and hemorrhagic strokes.

Recent filings

Filing Released Lang Actions
Application for quotation of securities - EMV 7 pages 29.8KB
Capital/Financing Update Classification · 95% confidence The document is an application for quotation of securities on the ASX, detailing the issuance and conversion of options into ordinary fully paid shares. It includes specifics about the number of securities, issue dates, and whether the securities are being issued for cash consideration. The document is regulatory in nature, related to capital changes but does not announce a new share issue or capital change in the form of a stock split or new share offering to the public. Instead, it is an official announcement related to the quotation of securities following option exercises. This fits best under the category of Capital/Financing Update (CAP), as it updates on securities issued due to option exercises and their quotation on the exchange.
2023-05-04 English
Cleansing Notice 1 page 130.4KB
Share Issue/Capital Change Classification · 95% confidence The document is a short notice from EMVision Medical Devices Limited regarding the issuance of shares following the exercise of options. It references compliance with sections of the Corporations Act 2001 and mentions an Appendix 2A announcement. The content is about a share issue and legal compliance notice related to securities issuance without disclosure. It is not a full financial report, earnings release, or management discussion. The document length is only 1625 characters, indicating it is a brief announcement rather than a detailed report. This fits the category of Share Issue/Capital Change (SHA), as it announces new shares issued and related regulatory compliance.
2023-05-04 English
Change of Director's Interest Notice 3 pages 278.2KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a company director, including shares and options exercised or cancelled. The content is focused on reporting personal share transactions by a director, including dates, number of securities, and nature of the transactions. This matches the definition of 'Director's Dealing' filings, which report personal share transactions by company directors and executives (insider trades). The document length is 4197 characters, which is consistent with a detailed notice rather than a brief announcement. Therefore, the correct classification is DIRS (Director's Dealing).
2023-05-04 English
Quarterly Activities/Appendix 4C Cash Flow Report 9 pages 288.0KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'APPENDIX 4C – 31 MARCH 2023 QUARTERLY ACTIVITIES & CASHFLOW REPORT' and provides detailed information on the company's quarterly activities, clinical trial progress, device development milestones, cash flow commentary, and cash reserves as of 31 March 2023. It includes substantive financial data such as cash inflows, outflows, grant funding, and operating expenses for the quarter. The document is approximately 15,000 characters long, indicating it is a comprehensive report rather than a brief announcement. The content aligns with a quarterly report providing financial and operational updates for a period shorter than a full fiscal year. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q3 2023
2023-04-26 English
Notification regarding unquoted securities - EMV 9 pages 37.0KB
Share Issue/Capital Change Classification · 100% confidence The document is a detailed notification about the issue of unquoted equity securities, specifically options issued under a new employee incentive plan. It includes specifics such as the number of securities issued, exercise prices, expiry dates, and the regulatory context under ASX listing rules. The document is not a financial report, earnings release, or management discussion, but rather an announcement of securities issuance and related compliance information. This fits the category of Share Issue/Capital Change (SHA), which covers announcements regarding new share issues or capital changes. The document length and detail confirm it is not a brief announcement or a report publication notice, but a substantive notification of capital changes.
2023-04-23 English
Product Development Milestones & Grant Funding Achieved 3 pages 321.3KB
Capital/Financing Update Classification · 95% confidence The document is a company announcement dated 17/04/23 from EMVision Medical Devices Ltd. It provides updates on product development milestones, grant funding, clinical trial progress, and collaborations. The content focuses on operational progress and funding achievements rather than financial results or detailed financial statements. There is no indication of quarterly or annual financial data, audit information, or regulatory filings. The document is a news release or corporate update about product development and grant receipt, which fits best under Capital/Financing Update (CAP) because it includes a significant grant funding announcement ($600,000 non-dilutive grant payment) and development milestones relevant to financing and capital progress. The document length (7635 characters) and content do not suggest it is a full financial report or regulatory filing. Therefore, the most appropriate classification is CAP with high confidence.
2023-04-16 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.